EXEL - Exelixis, Inc.
| Previous Close | 20.54 |
| Open | 20.58 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 4000 |
| Day's Range | 20.54 - 21.50 |
| 52 Week Range | 13.42 - 32.20 |
| Volume | 3,862,156 |
| Avg. Volume | 4,053,354 |
| Market Cap | 6.386B |
| Beta (3Y Monthly) | 3.04 |
| PE Ratio (TTM) | 18.21 |
| EPS (TTM) | 1.17 |
| Earnings Date | Feb 25, 2019 - Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.56 |
- Motley Fool•yesterday
Here's Why Exelixis Stock Jumped 46.4% in November
A third-quarter earnings surprise and a European approval gave the stock some lift.
- Zacks•5 days ago
Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx
Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.
- ACCESSWIRE•5 days ago
Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis
NEW YORK, NY / ACCESSWIRE / December 6, 2018 / U.S. markets fell in Tuesday amidst trade related uncertainty between the U.S. and China. The Dow Jones Industrial Average fell 3.10 percent to close at 25,027.07, ...
- Business Wire•6 days ago
Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma
ADR:IPSEY) today announced the initiation of COSMIC-312, a phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) versus sorafenib in previously untreated advanced hepatocellular carcinoma (HCC). An exploratory arm will also evaluate cabozantinib monotherapy in this first-line setting. “Liver cancer is the fastest-rising cause of cancer-related death in the U.S., underscoring the need for new treatment options for this patient community,” said Gisela Schwab, M.D., President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis.
- Zacks•7 days ago
Why Exelixis (EXEL) Could Be Positioned for a Surge
Exelixis (EXEL) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Market Realist•7 days agoWhy Clovis Oncology Stock Rose 48% in November
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30. Clovis Oncology’s stock price grew from $11.63 at the close of business on October 31 to $17.21 at the close of the market on November 30, which reflects ~48% growth in November.
Markit•7 days agoSee what the IHS Markit Score report has to say about Exelixis Inc.
Exelixis Inc NASDAQ/NGS:EXEL
Market Realist•8 days agoWhy Exelixis Stock Soared 46% in November
Exelixis stock rose from $13.87 at the close of markets on October 31, 2018, to reach $20.31 at the close of market on November 30, 2018, a ~46% increase over the last month. Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29, 2018. Exelixis stock experienced solid growth after the company released its third-quarter financial results on November 1, 2018.
- ACCESSWIRE•8 days ago
Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Exelixis
A “trade war truce” was expected to come from the dinner between President Trump and Chinese President Xi Jinping over the weekend and that is what exactly happened. China and the United States agreed to a ceasefire in their bitter trade war on Saturday, including no escalated tariffs in Jan. Trump will leave tariffs on $200 billion worth of Chinese imports at 10 percent at the beginning of the new year. The Nasdaq Composite Index climbed 0.79 percent to close at 7,330.54.
- Zacks•10 days ago
Why Is Exelixis (EXEL) Up 35.9% Since Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ACCESSWIRE•12 days ago
Biotech's Tackling Major Issues You Should Know
HENDERSON, NV / ACCESSWIRE / November 29, 2018 / Here are a few biotech/ healthcare and CBD companies that require your attention. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), MedMen ...
- Zacks•15 days ago
Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss
Spark Therapeutics (ONCE) announces approval in Europe for its gene therapy, Luxturna, for treating inherited retinal dystrophy with RPE65 mutation. Novartis will develop and distribute it in Europe.
- Simply Wall St.•15 days ago
Is Exelixis Inc’s (NASDAQ:EXEL) CEO Being Overpaid?
In 2010 Michael Morrissey was appointed CEO of Exelixis Inc (NASDAQ:EXEL). First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a snap Read More...
Markit•17 days agoSee what the IHS Markit Score report has to say about Exelixis Inc.
Exelixis Inc NASDAQ/NGS:EXEL
- Zacks•18 days ago
Sarepta Stock More Than Doubles This Year So Far: Here's Why
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.
- Business Wire•20 days ago
Exelixis Announces Webcasts of Investor Conference Presentations in November
- Presentations to be webcast on www.exelixis.com -
American City Business Journals•22 days agoHealth Care Digest: Chelsea Clinton's shout out, Verily shelves 'smart lens' for diabetes, an East Bay biotech's hunt for employees and more
Clover Health's flu shot-monitoring report was praised by Clinton — part of our weekly Health Care Digest roundup.
- Zacks•26 days ago
Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx
Exelixis (EXEL) and partner Ipsen receive EU approval for the label expansion of Cabometyx (cabozantinib) tablets as a monotherapy for HCC in adults.
- Benzinga•26 days ago
The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 14) Vapotherm, Inc. (NYSE: VAPO )(listed following its IPO) ...
Markit•26 days agoSee what the IHS Markit Score report has to say about Exelixis Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Business Wire•26 days ago
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib
Exelixis, Inc. (EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) tablets as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of CABOMETYX in this indication in all 28 member states of the European Union, Norway and Iceland.
- ACCESSWIRE•27 days ago
Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down ...
- ACCESSWIRE•27 days ago
Today's Research Reports on Trending Tickers: Exelixis and Agios Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / U.S. equities saw losses on Tuesday as continued weakness in oil prices pressured energy stocks lower. Crude oil dropped for the 12th consecutive session, ...
- Thomson Reuters StreetEvents•27 days ago
Edited Transcript of EXEL earnings conference call or presentation 1-Nov-18 9:00pm GMT
Q3 2018 Exelixis Inc Earnings Call
